bfw - I wholeheartedly agree that top line is not the only game in town.

The secondary end points could be end up being a much larger target than CVD however this is a CVD trial and a miss on the top line could be devastating.

For the secondary targets much more testing will be required which of course costs money that would have to be raised. We are on a just in time funding plan at this time so not a lot of funds to carry us through to new directions. IMO a miss on top line will come with a lot of short term pain, consolidation and dilution.

We will all be very grateful for a successful conclusion to this trial.

tada